Ortho Clinical Diagnostics Amends Credit Agreement to Extend Maturity and Increase Borrowing Capacity Under its Revolving Credit Facility
Ortho Clinical Diagnostics Holdings plc (Nasdaq: OCDX) announced on February 5, 2021, the amendment of its credit agreement, increasing its revolving credit facility by $150 million to a total of $500 million.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Ortho Clinical Diagnostics Holdings plc (Nasdaq: OCDX) announced on February 5, 2021, the amendment of its credit agreement, increasing its revolving credit facility by $150 million to a total of $500 million. The maturity date has been extended to February 26, 2026. This move is expected to enhance the company's liquidity, aiding in its operational capabilities. Detailed information can be found in an 8-K filing with the SEC.
Positive
- Revolving credit facility increased by $150 million, improving liquidity.
- Maturity date extended to 2026, providing financial stability.
Negative
- None.
Details
News Market Reaction – OCDX
The recorded move for OCDX in the trading session of this news was -0.28%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Increases facility by
RARITAN, N.J., Feb. 09, 2021 (GLOBE NEWSWIRE) -- Ortho Clinical Diagnostics Holdings plc (Nasdaq: OCDX) ("Ortho"), one of the world's largest pure-play in vitro diagnostics companies, today announced that certain of its subsidiaries successfully amended their June 30, 2014 credit agreement (the “Credit Agreement”) on February 5, 2021.
The amendment increases the revolving credit facility under the Credit Agreement by
The Company has filed an 8-K with the Securities and Exchange Commission with more information regarding the Amended Credit Agreement.
About Ortho Clinical Diagnostics
Ortho Clinical Diagnostics is a global leader of in vitro diagnostics dedicated to improving and saving lives through innovative laboratory testing and blood-typing solutions.
Because Every Test is a Life™, we never stop innovating to offer streamlined, sustainable laboratory solutions that deliver fast, accurate, reliable test results that support exceptional patient care.
As a trusted partner of hospitals, hospital networks, blood banks, and labs around the world, we proudly serve the clinical laboratory and transfusion medicine communities with customized solutions that enhance clinical outcomes, improve lab performance, overcome staffing challenges and better manage costs.
We are powered by Ortho Care™, our global, award-winning, holistic approach to service, which supports customers with best-in-class technical support, award-winning field support, and remote service and inventory support.
For more information about Ortho’s solutions and services, visit Ortho’s website or social media channels: LinkedIn, Twitter, Facebook and YouTube.
Investors:
IR@orthoclinicaldiagnostics.com
Media:
media@orthoclinicaldiagnostics.com
Source: Ortho Clinical Diagnostics
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.